Xifaxan Availability: A Briefing for Providers and Prescribers

As a provider who prescribes Xifaxan (Rifaximin), you've likely fielded calls from patients unable to fill their prescriptions. While Xifaxan is not in a formal FDA-listed shortage, access barriers are real and persistent. This article provides a comprehensive overview of the current situation and actionable strategies to support your patients.

Current Supply Status

As of February 2026, Rifaximin is not listed on the FDA Drug Shortages database. Salix Pharmaceuticals (Bausch Health) continues to manufacture Xifaxan as the sole U.S. supplier. Production appears stable, and no formal supply disruptions have been reported.

However, the functional availability of Xifaxan at the pharmacy level is another story. The combination of high acquisition cost, sole-source manufacturing, and insurance gatekeeping creates a de facto access gap that affects a significant subset of patients.

Timeline and Context

Xifaxan has been on the U.S. market since 2004 (originally approved for travelers' diarrhea). The 550 mg formulation gained additional approvals for hepatic encephalopathy (2010) and IBS-D (2015). Key timeline considerations:

• Patent status: Exclusivity expected through 2028-2029. No generic Rifaximin is available in the U.S.
• ANDA filings: Multiple generic manufacturers have filed abbreviated new drug applications, but none have reached market.
• Pricing trend: Wholesale acquisition cost has increased steadily since launch, with current retail prices of $1,600–$2,200 for a 30-day supply (550 mg, 60 tablets).

Prescribing Implications

The access challenges around Xifaxan have direct implications for clinical practice:

Prior Authorization Burden

Most commercial and Medicare Part D plans require prior authorization for Xifaxan. Common requirements include:

• Documented diagnosis of hepatic encephalopathy or IBS-D
• For HE: documentation of prior Lactulose use or concurrent Lactulose therapy (step therapy)
• For IBS-D: documentation of failed conventional therapies
• Specialist prescribing may be required by some plans

The PA process typically takes 24-72 hours but can extend to a week or more for appeals. For HE patients, treatment gaps during this period can precipitate encephalopathy episodes requiring hospitalization.

Formulary Placement

Xifaxan is typically placed on Tier 3 (preferred brand) or specialty tier, resulting in higher patient copays. Even with coverage, out-of-pocket costs can range from $50 to $200+ per month. The Xifaxan Instant Copay Savings Card can reduce this to $0 for commercially insured patients, but it is not valid for government insurance programs (Medicare, Medicaid, VA, TRICARE).

Pharmacy Stocking Patterns

Due to the high acquisition cost, many retail pharmacies don't maintain standing stock of Xifaxan. This means:

• Patients may face 1-3 day ordering delays even after insurance approval
• E-prescribing to a pharmacy without stock can create confusion and treatment gaps
• Specialty pharmacies are more likely to have consistent inventory

The Availability Picture

While supply from the manufacturer is adequate, distribution is uneven. Key patterns include:

• Specialty pharmacies focused on GI/hepatology have the most reliable stock
• Mail-order pharmacies through insurance plans generally maintain adequate supply
• Large chain pharmacies may or may not stock Xifaxan depending on local demand
• Independent pharmacies vary widely; some proactively stock it, others do not

Cost and Access Considerations

Understanding the full cost landscape helps you advise patients effectively:

• Cash price: $1,600–$2,200/month for HE dosing (550 mg BID, 60 tablets)
• Manufacturer savings card: $0 copay for eligible commercially insured patients (xifaxan.copaysavingsprogram.com)
• Patient Access Network (PAN) Foundation: Copay assistance for eligible patients
• Bausch Health Patient Assistance Program: Free medication for qualifying uninsured/underinsured patients
• Discount cards: SingleCare and similar programs offer modest discounts (e.g., ~$335 for 6 tablets of 550 mg)

For Medicare patients facing the coverage gap ("donut hole"), costs can be substantial. Directing these patients to the PAN Foundation early can prevent treatment interruptions.

Tools and Resources for Your Practice

Several tools can streamline the process of getting patients their medication:

Medfinder for Providers

Medfinder allows providers and staff to quickly identify pharmacies with Xifaxan in stock before sending a prescription. This reduces the risk of sending an e-prescription to a pharmacy that needs to order the drug, eliminating unnecessary delays.

Prior Authorization Best Practices

• Submit PAs proactively at the time of prescribing — don't wait for the pharmacy to trigger it
• Include all supporting documentation upfront (diagnosis, prior treatment history, lab values for HE patients)
• For HE patients, document concurrent Lactulose use to satisfy step therapy requirements
• Consider using electronic PA services integrated with your EHR to speed turnaround

Specialty Pharmacy Partnerships

Establishing a relationship with one or two specialty pharmacies that reliably stock Xifaxan can save your patients significant time and frustration. Many specialty pharmacies also handle PA paperwork and copay assistance enrollment on behalf of patients.

Alternative Therapies to Consider

When Xifaxan access is delayed, consider these clinically appropriate alternatives:

For Hepatic Encephalopathy:

• Lactulose: First-line therapy; may be sufficient as monotherapy for some patients; generic cost $10-$30/month
• Neomycin: Alternative antibiotic; limited by nephrotoxicity and ototoxicity with long-term use

For IBS-D:

• Eluxadoline (Viberzi): FDA-approved for IBS-D; contraindicated without gallbladder or with history of pancreatitis; Schedule IV
• Alosetron: Restricted to women with severe IBS-D; requires enrollment in prescribing program
• Loperamide: OTC symptom management; does not address underlying pathophysiology

For a comprehensive comparison, see our clinical overview of alternatives to Xifaxan.

Looking Ahead

Several developments may improve access in the coming years:

• Generic entry (2028-2029): Multiple ANDA filings suggest generic Rifaximin could reach market within 2-3 years, which would dramatically reduce costs and improve availability
• Biosimilar and reformulation activity: Ongoing pharmaceutical development in the GI space may yield new treatment options
• Policy changes: Growing scrutiny of drug pricing and prior authorization practices may lead to streamlined access requirements

Final Thoughts

Xifaxan remains an important therapeutic option for hepatic encephalopathy and IBS-D, but access barriers persist in 2026. By leveraging tools like Medfinder, proactively managing prior authorizations, and establishing specialty pharmacy relationships, you can minimize treatment disruptions for your patients.

For additional resources, explore our provider guides on helping patients find Xifaxan in stock and helping patients save money on Xifaxan.